Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesDexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
British Journal of Cancer, 07/24/09
Popelova O et al. – The study identifies inhibition of apoptosis as an important target for effective cardioprotection against chronic anthracycline cardiotoxicity and suggests that lipoperoxidation–independent mechanisms are involved in the cardioprotective action of DEX.
Related Articles
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
Journal of Clinical Oncology, 10/30/09
Relevance Score: 93%
Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia
Journal of Clinical Oncology, 11/03/09
Relevance Score: 88%
Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era
The Oncologist, 10/28/09
Relevance Score: 88%
Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia
Pediatric Blood & Cancer, 10/29/09
Relevance Score: 87%
Predicting anthracycline benefit: have we made any progress
Current Opinion in Oncology, 10/12/09
Relevance Score: 87%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer
Medical Oncology, 12/17/09
Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4?,5-trimethoxylstilbene-3?-O-phosphate disodium (M410)
Investigational New Drugs, 12/17/09
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/17/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors
Neuro-Oncology, 12/17/09
Oxaliplatin-induced Lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity
Oncology (Karger), 12/16/09
A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL)
Cancer, 12/16/09
Sponsor
Article Search
Sponsor
Sponsor